Testosterone and diurnal rhythmicity of leptin, TNF-α and TNF-II receptor in insulin-resistant myotonic dystrophy patients

International Journal of Obesity

Volumn 26, Issue 10, 2002, Pages 1386-1392

  Johansson, A ^a   Ahren B ^b   Forsberg, H ^c   Olsson, T ^a  

^a UMEÅ UNIVERSITY HOSPITAL   (Sweden)

^b LUND UNIVERSITY   (Sweden)

^c SUNDERBY HOSPITAL   (Sweden)

Author keywords

Insulin resistance; Leptin; Myotonic dystrophy; Testosterone; TNF; TNF receptor

Indexed keywords

LEPTIN; TESTOSTERONE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR 2;

ADULT; ARTICLE; BLOOD SAMPLING; BODY FAT; BODY MASS; CIRCADIAN RHYTHM; CLINICAL ARTICLE; DIET RESTRICTION; FEMALE; FIBRINOLYSIS; HUMAN; HYPOGONADISM; IMPAIRED GLUCOSE TOLERANCE; INSULIN RESISTANCE; MALE; METABOLIC REGULATION; MYOTONIC DYSTROPHY; PRIORITY JOURNAL; SAMPLING;

ADULT; ANTIGENS, CD; BODY COMPOSITION; CASE-CONTROL STUDIES; CIRCADIAN RHYTHM; ELECTRIC IMPEDANCE; FASTING; FEMALE; HUMANS; INSULIN; INSULIN RESISTANCE; LEPTIN; MALE; MIDDLE AGED; MYOTONIC DYSTROPHY; RECEPTORS, TUMOR NECROSIS FACTOR; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE II; TESTOSTERONE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0036799745     PISSN: 03070565     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.ijo.0802078     Document Type: Article

References (35)

1. Alberti KGMM, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: Diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 1998; 15: 539-553.
2. Harper PS. Myotonic Dystrophy. 2nd Edn. WB Saunders: London, 1989.
3. Moorjani S, Gaudet D, Laberge C, Thibault MC, Mathieu J, Morissette J, Lupien PJ, Brun D, Gagné C. Hypertriglyceridemia and lower LDL cholesterol concentration in relation to apolipoprotein E phenotypes in myotonic dystrophy. Can J Neurol Sci 1989; 16: 129-133.
4. Fernández-Real JM, Molina A, Broch M, Rocart W, Gutiérrez C, Casamitjana R, Vendrell J, Soler J, Gómez-Sáez JM. Tumor necrosis factor system activity is associated with insulin resistance and dyslipidemia in myotonic dystrophy. Diabetes 1999; 48: 1108-1112.
5. Gómez JM, Molina A, Férnandez-Castañer M, Casamitjana R, Martínez-Matos JA, Soler J. Insulin regulation of leptin synthesis and secretion in humans: The model of myotonic dystrophy. Clin Endocrinol 1999; 50: 569-575.
6. Hotamisligil GS, Spiegelman BM. Tumor necrosis factor α: A key component of obesity-diabetes link. Diabetes 1994; 43: 1271-1278.
7. Söderberg S, Olsson T, Eliasson M, Johnson O, Ahrén B. Plasma leptin levels are associated with abnormal fibrinolysis in men and postmenopausal women. J Intern Med 1999; 245: 533-543.
8. Björntorp P, Rosmond R. The metabolic syndrome - A neuroendocrine disorder? Br J Nutr 2000; 83 (suppl 1): S49-S57.
9. Johannson Å, Henriksson A, Olofsson B-O, Olsson T. Adrenal steroid dysregulation in dystrophia myotonica. J Intern Med 1999; 245: 345-351.
10. Johansson A, Ahrén B, Carlström K, Forsberg H, Krylborg E, Cederquist K, Olsson T. Abnormal cytokine and adrenocortical hormone regulation in myotonic dystrophy. J Clin Endocrinol Metab 2000; 85: 3169-3176.
11. Johansson Å, Boman K, Cederquist K, Forsberg H, Olsson T. Increased levels of tPA and tPA/PAI-1 complex in myotonic dystrophy. J Intern Med 2001; 249: 503-510.
12. Ahrén B, Larsson H, Wilhelmsson C, Näsman B, Olsson T. Regulation of circulating leptin in humans. Endocrine 1997; 7: 1-8.
13. Saladin R, De Vos P, Guerre-Millo M, Leturque A, Girard J, Staels B, Aurwerx J. Transient increase in obese gene expression after food intake or insulin administration. Nature 1995; 377: 527-529.
14. Kirchgessner T, Uysal K, Wiesbrock S, Marino M, Hotamisligil G. Tumor necrosis factor-a contributes to obesity-related hyperleptinemia by regulating leptin release from adipocytes. J Clin Invest 1997; 100: 2777-2782.
15. Zakrzewska K, Cusin I, Sainsbury A, Rohner-Jeanrenaud F, Jean-renaud B. Glucocorticoids as counterregulatory hormones of leptin. Toward an understanding of leptin resistance. Diabetes 1997; 46: 717-719.
16. Hotamisligil GS, Shargill N, Spiegelman BM. Adipose expression of tumor necrosis factor-α: Direct role in obesity-linked insulin resistance. Science 1993; 259: 87-91.
17. Sethi JK, Hotamisligil GS. The role of TNFa in adipocyte metabolism. Cell Devl Biol 1999; 10: 19-29.
18. Tartaglia LA, Goeddel DV. Two TNF receptors. Immunol Today 1992; 13: 151-153.
19. Mohamed-Ali V, Pinkney JH, Coppack SW. Adipose tissue as an endocrine and paracrine organ. Int J Obes Relat Metab Disord 1998; 22: 1145-1158.
20. Hotamisligil GS, Arner P, Atkinson RL, Spiegelman BM. Differential regulation of the p80 tumor necrosis factor receptor in human obesity and insulin resistance. Diabetes 1997; 46: 451-455.
21. Jockenhövel F, Blum WF, Vogel E, Englaro P, Müller-Wieland D, Reinwein D, Rascher W, Krone W. Testosterone substitution normalizes elevated serum leptin levels in hypogonadal men. J Clin Endocrinol Metab 1997; 82: 2510-2513.
22. Sih R, Morley J, Kaiser F, Perry H III, Patrick P, Ross C. Testosterone replacement in older hypogonadal men: A 12-month randomized controlled trial. J Clin Endocrinol Metab 1997; 82: 1661-1667.
23. Forsberg H. Cardiac Involvement in Myotonic Dystrophy. Thesis. Umeå University, Sweden, 1990.
24. Sambrook J, Fritsch EF, Maniatis T. Molecular Cloning. A Laboratory Manual. Cold Spring Harbor Laboratory Press, Old Spring Harbor, NY, 1989.
25. Brook JD, McCurrah ME, Harley HG, Buckler AJ, Church D, Aburatani H, Hunter K, Stanton VP, Thirion J-P, Hudson T, Sohn R, Zemelman B, Snell RG, Rundle SA, CrowS, Davies J, Shelbourne F, Buxton J, Jones C, Juvonen V, Johnson K, Harper PS, Shaw DJ, Housman DE. Molecular basis of myotonic dystrophy: Expansion of a triplet (CTG) repeat at the 3′ end of a transcript encoding a protein kinase family member. Cell 1992; 68: 799-808.
26. Gomez JM, Molina A, Fernandez-Castaner M, Soler J. Leptin in type 2 diabetic or myotonic dystrophic women. Horm Metab Res 2001; 33: 246-249.
27. Rosenbaum M, Leibel RL. Role of gonadal steroids in the sexual dimorphisms in body composition and circulating concentrations of leptin. J Clin Endocrinol Metab 1999; 84: 1784-1789.
28. Ceddia RB, William WNJ, Curi R. The response of skeletal muscle to leptin. Front Biosci 2001; 6: D90-D97.
29. Morrone A, Pegoraro E, Angelini C, Zammarchi E, Marconi G, Hoffman EP. RNA metabolism in myotonic dystrophy. Patient muscle shows decreased insulin receptor RNA and protein consistent with abnormal insulin resistance. J Clin Invest 1997; 99: 1691-1698.
30. Hotamisligil GS, Peraldi P, Budavari A, Ellis R, White MF, Spiegelman BM. IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-α and obesity-indiced insulin resistance. Science 1996; 271: 665-668.
31. Furling D, Marette A, Puymirat J. Insulin-like growth factor I circumvents defective insulin action in human myotonic dystrophy skeletal muscle cells. Endocrinology 1999; 140: 4244-4250.
32. Aderka D, Engelmann H, Maor Y, Brakebusch C, Wallach D. Stabilization of the bioactivity of tumor necrosis factor by its soluble receptors. J Exp Med 1992; 175: 323-329.
33. Fernández-Real J-M, Broch M, Ricart W, Casamitjana R, Gutierrez C, Vendrell J, Richart C. Plasma levels of the soluble fraction of tumor necrosis factor receptor 2 and insulin resistance. Diabetes 1998; 47: 1757-1762.
34. Rönnemaa T, Pulkki K, Kapiro J. Serum soluble tumor necrosis factor-a receptor 2 is elevated in obesity but is not related to insulin sensitivity: A study in identical twins discordant for obesity. J Clin Endocrinol Metab 2000; 85: 2728-2732.
35. Mohamed-Ali V, Goodrick S, Bulmer K, Holly JM, Yudkin JS, Coppack SW. Production of soluble tumor necrosis factor receptors by human subcutaneous adipose tissue in vivo. Am J Physiol 1999; 277: E971-E975.